Clinical Program Director
CSL Behring
King of Prussia, Pennsylvania, United States
Paul M Shore, MD MS is a pediatric critical care and emergency medicine physician who is the clinical program director of CSL Behring’s CSL889 program for the acute treatment of vaso-occlusive crisis in sickle cell disease. He received his MD from Hahnemann University in Philadelphia, which is now Drexel University College of Medicine, and a Masters in Clinical Research from the University of Pittsburgh. Dr. Shore completed residency in General Pediatrics and fellowship in Pediatric Critical Care Medicine at Children’s Hospital of Pittsburgh, and a fellowship in Pediatric Neurointensive Care and Resuscitation at the Safar Center for Resuscitation Research. Following over ten years in academic practice at Children’s Medical Center Dallas and St. Christopher’s Hospital for Children in Philadelphia, he pivoted to clinical drug development in industry. After starting in the respiratory space at Teva Pharmaceuticals, he turned his focus to rare disease at Windtree Pharmacuticals in neonatology, then at CSL Behring where he has focused on organ transplantation, critical respiratory disease and currently sickle cell disease. He also continues to practice Pediatric Emergency Medicine at St. Christopher’s Hospital for Children, where he regularly treats children and young adults with sickle cell disease.
Disclosure information not submitted.
CSL889 (Hemopexin) and Vamifeport as Potential Therapeutics in Sickle Cell Disease
Friday, June 16, 2023
5:05 PM – 5:15 PM East Coast USA Time
Friday, June 16, 2023
5:15 PM – 5:30 PM East Coast USA Time